Bloomberg: Vaccine Makers Can Skip U.S. Inspections

Bloomberg: Vaccine Makers Can Skip U.S. Inspections. “The U.S. Food and Drug Administration inspects a few thousand drug manufacturing plants every year to ensure their standards are up to par. Many of those inspections are required before a pharmaceutical company can gain approval of a new drug. They serve as a check on whether drugmakers can produce quality therapies. But that won’t be the case for Covid-19 vaccine developers that gain emergency authorization of a shot.”

Leave a Reply